Saram ConsultingGxP & AI Consulting for Life Sciences. Custom AI integrations, Part 11 compliance validation, and equity-based engineering partnerships for biotech.Explore Services at saram.io →
← Back to Home

Genetix Biotherapeutics

Private

Genetix Biotherapeutics is the rebranded gene therapy company formerly known as bluebird bio, owned by investment funds managed by The Carlyle Group and SK Capital Partners. It manufactures and sells lentiviral gene therapies for severe genetic blood and neurological disorders.

Company Info

Sector:Gene Therapy
Headquarters:Somerville, MA, USA
Founded:1992

Clinical Development Pipeline

Zynteglo (betibeglogene autotemcel)

Target: BCL11A / beta-globin gene addition
Transfusion-dependent beta-thalassemia
Preclinical
Phase 1
Phase 2
Phase 3
Approved

Lyfgenia (lovotibeglogene autotemcel)

Target: Anti-sickling beta-globin gene addition
Sickle cell disease with vaso-occlusive events
Preclinical
Phase 1
Phase 2
Phase 3
Approved

Skysona (elivaldogene autotemcel)

Target: ABCD1 gene addition
Early cerebral adrenoleukodystrophy
Preclinical
Phase 1
Phase 2
Phase 3
Approved

Recent News

Leadership Team

Careers & Job Openings

See all open roles

Manufacturing / Clinical
Somerville, MA
Apply Now →